Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the publication of clinical results from the ovarian cancer cohort of its Phase 1b C-800-01 trial evaluating ...

Regulatory T (Treg) cells, identified over two decades ago, are pivotal in maintaining immune tolerance and preventing autoimmunity. Extensive research has ...

Adagene Inc. ADAG announced that the FDA has granted Fast Track designation to its lead clinical-stage immuno-oncology ...

The FDA's fast track designation acknowledges the combination's promising early efficacy and safety profile in treating MSS mCRC. Early data from a phase 1b/2 study showed deep, durable responses with ...

The U.S. Food and Drug Administration (FDA) has granted fast track designation to muzastotug when used in combination with Keytruda (pembrolizumab) to treat adult patients with microsatellite stable ...

Shares of Adagene Inc. (NASDAQ:ADAG) jumped more than 16% in pre-market trading on Tuesday after the biotech company said the ...

Neoantigen vaccines are at the forefront of cancer research, driving personalized immunotherapy and improving outcomes ...

Investing.com -- Adagene Inc (NASDAQ:ADAG) stock surged 16.3% in premarket trading Tuesday after the company announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation ...

Designation underscores the potential of SAFEbody®-enabled anti-CTLA-4 therapy to address unmet need in MSS colorectal ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced FDA approval to initiate COMPASSION-37/AK104-311 trial, a global multicenter Phase III trial in gastric cancer evaluating cadonilimab, a ...

Theresa Walunas, PhD, FAMIA, is an associate professor of Medicine in the Division of General Internal Medicine and Geriatrics, Microbiology-Immunology and Preventive Medicine in the Division of ...